Evidence map›Paper›PMID 37238080›Full record

ReviewAnimals : an open access journal from MDPI2023

Jacob van der Ende, Henk D F H Schallig

Open access · goldAbstract readReview
In one paragraph

Review in Animals : an open access journal from MDPI, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Brain Involvement in Leishmaniasis.Cell biochemistry and function · 2026
    Review
  6. Review
  7. Article
  8. Indazole Derivatives Against Murine Cutaneous Leishmaniasis.Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  9. Review
  10. Review
  11. Anti-Antimicrobial agents and chemotherapy · 2024
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jacob van der EndeFundación Quina Care Ecuador, Puerto el Carmen de Putumayo 210350, Sucumbíos, Ecuador.
Henk D F H SchalligExperimental Parasitology Unit, Amsterdam University Medical Centres, Department of Medical Microbiology and Infection Prevention, Academic Medical Centre at the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0002-7096-6279
University of Amsterdam · NL

Funding

Netherlands Organisation for Health Research and Development 1 1 40241 10
6 · The paper itself

Abstract

Many different animal models are in use for drug development for leishmaniasis, but a universal model does not exist. There is a plethora of models, and this review assesses their design, quality, and limitations, including the attention paid to animal welfare in the study design and execution. A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines of available literature after the year 2000 describing animal models for leishmaniasis. The risk of bias was determined using the SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) risk of bias assessment tool. A total of 10,980 records were initially identified after searching the databases PubMed, EMBASE, LILACS, and SciELO. Based on the application of predetermined exclusion and inclusion criteria, a total of 203 papers describing 216 animal experiments were available for full analysis. Major reasons for exclusion were a lack of essential study information or appropriate ethical review and approval. Mice (82.8%; an average of 35.9 animals per study) and hamsters (17.1%; an average of 7.4 animals per study) were the most frequently used animals, mostly commercially sourced, in the included studies. All studies lacked a formal sample size analysis. The promastigote stages of

Indexed as

animal studiesdrugsLeishmanialeishmaniasis

Identifiers

PMID37238080
PMCPMC10215483
OpenAlexW4377044111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.